Survodutide is investigational glucagon/GLP-1 dual receptor agonist (Boehringer Ingelheim). Survodutide is an experimental weekly injection that acts on two hormone receptors, glucagon and GLP-1. It is studied for obesity and for fatty liver disease (MASH).
Education only. Not medical advice. No dosing information.
Status (verified Oct 29, 2026): Investigational: Phase 3 (SYNCHRONIZE) results published 2026; not approved. Source: SYNCHRONIZE-1 published in NEJM: -13.0% vs -5.4% placebo at 76 weeks
Evidence tier: Phase 3 trials
Get alerts on legal status changes ->
What it is
Survodutide is an experimental weekly injection that acts on two hormone receptors, glucagon and GLP-1. It is studied for obesity and for fatty liver disease (MASH).
How it works
GLP-1 activity lowers appetite; glucagon activity may raise energy use and reduce liver fat.
What it's researched for
Obesity, cardiovascular outcomes in obesity, and MASH (fatty liver).
Where it shows up on Peptide Horizon
Regulatory and research timeline
- 2025-01: SYNCHRONIZE Phase 3 designs published (source)
- 2026: SYNCHRONIZE-1 published in NEJM: -13.0% vs -5.4% placebo at 76 weeks (source)
Key trials and studies
- SYNCHRONIZE-1 (NEJM 2026)
- SYNCHRONIZE-1/-2 design (Obesity 2025)
- SYNCHRONIZE-CVOT design (JACC Heart Fail 2024)
FAQ
Is survodutide FDA approved?
No. It has completed Phase 3 obesity trials but is not approved.
How is survodutide different from semaglutide?
It adds glucagon receptor activity to GLP-1 activity.
Why is survodutide studied for the liver?
Glucagon signaling may help reduce liver fat, so it is being studied in MASH.
Related peptides
- mazdutide FDA status and research
- retatrutide FDA status and research
- tirzepatide FDA status and research
Get alerts on legal status changes
Free email alerts when the FDA, HHS or another regulator changes the status of Survodutide or other peptides. Get alerts ->
Sources
- https://www.nejm.org/doi/full/10.1056/NEJMoa2600751
- https://pubmed.ncbi.nlm.nih.gov/39495965
- https://pubmed.ncbi.nlm.nih.gov/39453356
Editorial review - Last reviewed Oct 29, 2026